JP2015517580A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517580A5
JP2015517580A5 JP2015514233A JP2015514233A JP2015517580A5 JP 2015517580 A5 JP2015517580 A5 JP 2015517580A5 JP 2015514233 A JP2015514233 A JP 2015514233A JP 2015514233 A JP2015514233 A JP 2015514233A JP 2015517580 A5 JP2015517580 A5 JP 2015517580A5
Authority
JP
Japan
Prior art keywords
fluorophenyl
pyrazolo
methanone
hexahydro
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015514233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517580A (ja
JP6172871B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042732 external-priority patent/WO2013177559A2/en
Publication of JP2015517580A publication Critical patent/JP2015517580A/ja
Publication of JP2015517580A5 publication Critical patent/JP2015517580A5/ja
Application granted granted Critical
Publication of JP6172871B2 publication Critical patent/JP6172871B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015514233A 2012-05-25 2013-05-24 ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子 Active JP6172871B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201261651669P 2012-05-25 2012-05-25
US61/651,669 2012-05-25
US201261691083P 2012-08-20 2012-08-20
US61/691,083 2012-08-20
US201261715907P 2012-10-19 2012-10-19
US61/715,907 2012-10-19
US201361759520P 2013-02-01 2013-02-01
US61/759,520 2013-02-01
US201361781629P 2013-03-14 2013-03-14
US61/781,629 2013-03-14
PCT/US2013/042732 WO2013177559A2 (en) 2012-05-25 2013-05-24 Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
JP2015517580A JP2015517580A (ja) 2015-06-22
JP2015517580A5 true JP2015517580A5 (US06653308-20031125-C00057.png) 2016-06-23
JP6172871B2 JP6172871B2 (ja) 2017-08-02

Family

ID=49624542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514233A Active JP6172871B2 (ja) 2012-05-25 2013-05-24 ヘテロアリール‐ケトン縮合アザデカリン糖質コルチコイドレセプター調節因子

Country Status (23)

Country Link
EP (6) EP3851107B1 (US06653308-20031125-C00057.png)
JP (1) JP6172871B2 (US06653308-20031125-C00057.png)
KR (1) KR102062640B1 (US06653308-20031125-C00057.png)
CN (1) CN104619328B (US06653308-20031125-C00057.png)
AU (1) AU2013266110C1 (US06653308-20031125-C00057.png)
BR (1) BR112014028857B1 (US06653308-20031125-C00057.png)
CA (1) CA2872260C (US06653308-20031125-C00057.png)
CL (1) CL2014003173A1 (US06653308-20031125-C00057.png)
DK (5) DK2854814T3 (US06653308-20031125-C00057.png)
ES (4) ES2930298T3 (US06653308-20031125-C00057.png)
HK (2) HK1208818A1 (US06653308-20031125-C00057.png)
IL (1) IL235868A (US06653308-20031125-C00057.png)
MX (1) MX365423B (US06653308-20031125-C00057.png)
MY (1) MY172739A (US06653308-20031125-C00057.png)
NZ (1) NZ701469A (US06653308-20031125-C00057.png)
PE (1) PE20150352A1 (US06653308-20031125-C00057.png)
PH (1) PH12014502584B1 (US06653308-20031125-C00057.png)
PL (4) PL3338781T3 (US06653308-20031125-C00057.png)
PT (5) PT3338781T (US06653308-20031125-C00057.png)
RU (1) RU2639867C2 (US06653308-20031125-C00057.png)
SG (1) SG11201407682TA (US06653308-20031125-C00057.png)
WO (1) WO2013177559A2 (US06653308-20031125-C00057.png)
ZA (1) ZA201408182B (US06653308-20031125-C00057.png)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
DK3074011T3 (da) * 2013-11-25 2019-09-30 Corcept Therapeutics Inc Octahydro-kondenserede azadecalin-glucocorticoidreceptormodulatorer
WO2016140867A1 (en) * 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors
CA2978960C (en) 2015-03-30 2023-05-02 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20240014584A (ko) * 2015-05-18 2024-02-01 코어셉트 쎄라퓨틱스 인코포레이티드 쿠싱 증후군을 진단하고 이에 대한 치료를 평가하는 방법
ES2865334T3 (es) 2015-08-13 2021-10-15 Corcept Therapeutics Inc Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH
AU2017228329B2 (en) * 2016-03-01 2021-03-11 Corcept Therapeutics, Inc. The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
MX2019011543A (es) 2017-03-31 2019-12-16 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
CA3065555A1 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
WO2019209693A1 (en) * 2018-04-23 2019-10-31 Corcept Therapeutics, Inc. Methods of preparing regioselective n-alkyl triazoles
CN113015528A (zh) * 2018-11-09 2021-06-22 科塞普特治疗公司 缩小垂体肿瘤的方法
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
JP7444889B2 (ja) * 2018-12-20 2024-03-06 コーセプト セラピューティクス, インコーポレイテッド ソマトスタチン受容体陽性腫瘍のイメージング及び治療のための方法
AU2020226863B2 (en) 2019-02-22 2023-04-06 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
AU2020367769B2 (en) * 2019-10-16 2023-10-12 Corcept Therapeutics Incorporated Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist
UA128573C2 (uk) 2019-12-11 2024-08-14 Корсепт Терапьютікс Інкорпорейтед Способи лікування підвищення маси тіла, індукованого антипсихотичними засобами, за допомогою мірикориланту
WO2021127376A1 (en) 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN116829556A (zh) * 2021-02-03 2023-09-29 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用
WO2024077169A1 (en) * 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
WO2024173745A1 (en) * 2023-02-17 2024-08-22 Corcept Therapeutics Incorporated Methods and compositions for treating huntington's disease and its symptoms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
ATE407934T1 (de) * 2004-03-09 2008-09-15 Corcept Therapeutics Inc Azadecalinverbindungen mit kondensiertem ring als glucocorticoidrezeptormodulatoren
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2012027702A1 (en) * 2010-08-27 2012-03-01 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators

Similar Documents

Publication Publication Date Title
JP2015517580A5 (US06653308-20031125-C00057.png)
RU2014152625A (ru) Конденсированные с гетероарилкетонами азадекалины - модуляторы глюкокортикоидных рецепторов
JP2018535999A5 (US06653308-20031125-C00057.png)
RU2317291C2 (ru) Производные пиримидина в качестве модуляторов рецептора инсулинподобного фактора роста 1 (igf-1), фармацевтическая композиция, способы получения (варианты) и применение
JP2008501673A5 (US06653308-20031125-C00057.png)
RU2457207C2 (ru) Активаторы глюкокиназы
JP2010533158A5 (US06653308-20031125-C00057.png)
IL273705B2 (en) Benzothiazole compounds and methods of using them for the treatment of neurodegenerative diseases
HRP20191327T1 (hr) 4-hidroksi-3-(heteroaril)piridin-2-on apj agonisti za primjenju u liječenju kardiovaskularnih poremećaja
RU2016123449A (ru) Октагидро конденсированные азадекалиновые модуляторы глюкокортикоидного рецептора
JP2007523142A5 (US06653308-20031125-C00057.png)
JP2007523905A5 (US06653308-20031125-C00057.png)
JP2009536196A5 (US06653308-20031125-C00057.png)
HRP20200440T1 (hr) 1h-pirazolo[4,3-b]piridini kao pde1 inhibitori
JP2006503009A5 (US06653308-20031125-C00057.png)
CA2747419A1 (en) Sulfonamide derivatives
IL196129A (en) Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis
RU2015132181A (ru) Фтор-[1,3]-оксазины в качестве ингибиторов васе1
HRP20211960T1 (hr) Alosterični modulatori nikotinskih acetilcolinskih receptora
JP2007519735A5 (US06653308-20031125-C00057.png)
JP2013517264A5 (US06653308-20031125-C00057.png)
JP2017500364A5 (US06653308-20031125-C00057.png)
JP2020536116A5 (US06653308-20031125-C00057.png)
JP2017532364A5 (US06653308-20031125-C00057.png)
JP2016523976A5 (US06653308-20031125-C00057.png)